Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMULTAI)

Drug Name
Imidazo[1,2-b]pyridazine derivative 1 Drug Info
Synonyms PMID28270010-Compound-Figure22-1
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Patented [1]
Cross-matching ID
PubChem CID
72695720
TTD Drug ID
DMULTAI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Tropomyosin-related kinase A (TrkA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Entrectinib DMMPTLH Non-small-cell lung cancer 2C25 Approved [2]
Repotrectinib DM9FB2T Non-small-cell lung cancer 2C25 Approved [3]
Larotrectinib DM26CQR Solid tumour/cancer 2A00-2F9Z Approved [4]
MIM-D3 DMZHN5B Alzheimer disease 8A20 Phase 3 [5]
SNA-120 DMPN314 Plaque psoriasis EA90.0 Phase 2 [6]
CT 327 DMQXL1T Plaque psoriasis EA90.0 Phase 2 [7]
ONO-7579 DMXLPYE Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
Altiratinib DMUJCBT Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
PLX7486 DM0IVGU Pancreatic cancer 2C10 Phase 1 [8]
DS-6051 DM0RD4F Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Proto-oncogene c-Ros (ROS1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [10]
Lorlatinib DMICDLV Non-small-cell lung cancer 2C25.Y Approved [4]
Entrectinib DMMPTLH Non-small-cell lung cancer 2C25 Approved [2]
Repotrectinib DM9FB2T Non-small-cell lung cancer 2C25 Approved [3]
AB-106 DMEW62S Non-small-cell lung cancer 2C25 Phase 2 [11]
DS-6051 DM0RD4F Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
Carboxamide derivative 4 DMU5GKC N. A. N. A. Patented [12]
Imidazo[1,2-b]pyridazine derivative 2 DM1JYNW Solid tumour/cancer 2A00-2F9Z Patented [1]
Imidazo[1,2-b]pyridazine derivative 3 DMPDTG0 Solid tumour/cancer 2A00-2F9Z Patented [1]
PMID28270010-Compound-Figure21-b DM6IYAT Brain metastases 2D50 Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proto-oncogene c-Ros (ROS1) TTSZ6Y3 ROS1_HUMAN Inhibitor [1]
Tropomyosin-related kinase A (TrkA) TTTDVOJ NTRK1_HUMAN Inhibitor [1]

References

1 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8.
8 National Cancer Institute Drug Dictionary (drug id 747694).
9 National Cancer Institute Drug Dictionary (drug id 766123).
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
11 Clinical pipeline report, company report or official report of AnHeart Therapeutics.
12 RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.